Research presented at the ASCO Annual Meeting 2024 revealed new insights into HER2-low breast cancer, including a new ...
The greatest differences between LGBTQ+ and non-LGBTQ+ survivors were seen for cognitive limitations (37.9% vs 15.9%, P <.001), depressive disorders (48.5% vs 29.5%, P <.001), difficulty walking (31.4 ...
The ViPOR regimen produced durable remissions in patients with certain subtypes of relapsed or refractory DLBCL.
“Trametinib was safe and effective in young children with relapsed or refractory JMML, a lethal disease with poor survival rates,” the researchers wrote. “Seven of 10 patients completed the maximum 12 ...
Research presented at ASCO 2024 highlighted treatments that may improve outcomes for patients with metastatic breast cancer.
T-cell lymphoma was identified in 1 patient who received axicabtagene ciloleucel for diffuse large B-cell lymphoma.
The US Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel followed by Keytruda monotherapy for the treatment of adults with primary ...
Months into a new Biden administration policy intended to lower drug costs for Medicare patients, independent pharmacists say they’re struggling to afford to keep some prescription drugs in stock.
Trials presented at ASCO 2024 highlighted advances in Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and NK/T-cell lymphoma.
However, sexual dysfunction varied by cancer type. Sexual dysfunction was reported in 47% of CNS tumor survivors, 27% of Hodgkin lymphoma survivors, 26% of sarcoma survivors, 21% of leukemia survivors ...
The US Food and Drug Administration (FDA) has granted traditional approval to Retevmo (selpercatinib) to treat patients 2 years of age and older with advanced or metastatic RET fusion-positive thyroid ...
Johnson & Johnson will pay $700 million to settle claims that the company continued to market its talcum powder products even as evidence tied them to a heightened risk of cancer.